Jul 09, 2019
Global Cinnamon Market 2019-2024: Significant Rise in Adoption in the Pharmaceutical and Cosmetic Industry
Jun 25, 2019
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
May 08, 2019
The First-ever Practitioner Line of Keto Products with Allulose Continues Designs for Health's Standard of Excellence in Innovation
Apr 30, 2019
Caspofungin Market to Touch US$ 496.20 Million by 2027, Says TMR
Apr 08, 2019
F2G Appoints Dr. Patrick Vink as Chairman
Mar 22, 2019
Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe
Feb 28, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Feb 19, 2019
Antifungal Drugs Market Worth $17.72 Billion by 2023 at 3.7% CAGR, Says AMR
Feb 11, 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
Jan 30, 2019
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
Jan 07, 2019
F2G Expands Investor Syndicate and Progresses Phase 2b Study for Novel Antifungal
Dec 08, 2018
Global Undecylenic Acid Market 2018-2022 | Use of Undecylenic Acids as Feedstocks for the Synthesis of Polyurethanes and Polyols to Boost Growth | Technavio
Nov 21, 2018
Global Undecylenic Acid Market 2018-2022: Additive Manufacturing - The Way Forward for the Market - ResearchAndMarkets.com
Nov 13, 2018
Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
Oct 15, 2018
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
Sep 20, 2018
The Future of the Global Boric Acid Market to 2025 - Growth Opportunities, Competition Analysis and Key Trends - ResearchAndMarkets.com
Aug 09, 2018
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
Jul 18, 2018
The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
Jun 11, 2018
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
May 24, 2018
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018